Exosome-Mimicking Nanoparticles: Next-Generation Therapeutics for Obesity-Induced Type 2 Diabetes
Muhindo Edgar
Department of Pharmacy Kampala International University Uganda
Email: edgar.muhindo@studwc.kiu.ac.ug
ABSTRACT
Obesity-induced type 2 diabetes (T2D) emerges from sustained nutrient surplus, low-grade inflammation, and interorgan crosstalk that locks adipose tissue, liver, skeletal muscle, and pancreatic islets into insulin-resistant states. Exosomes – 30–150 nm extracellular vesicles are central messengers in this network, shuttling microRNAs, proteins, and lipids that remodel recipient cell programs. Native exosomes show therapeutic promise but face practical barriers: heterogeneous composition, low yield, batch variability, and concerns about immunogenicity and scalability. Exosome-mimicking nanoparticles (EMNs) seek to capture exosomal advantages like biophysical architecture, ligand-guided tropism, and efficient cellular entry while enabling reproducible, cGMP-ready manufacture. Built from lipids, polymers, or membrane-cloaked hybrids, EMNs can be engineered for organ selectivity and loaded with small molecules, peptides, RNAs, and genome editors to recalibrate insulin signaling, mitochondrial function, and inflammatory tone. Rational design uses exosomal lipidomics, integrin-mimetic motifs, and glycoconjugates to improve uptake and endosomal escape, while tuning size, stiffness, and surface chemistry to navigate the reticuloendothelial system characteristic of obesity. Preclinical studies in diet-induced models demonstrate improvements in hepatic steatosis, adipose inflammation, skeletal muscle oxidative metabolism, and β-cell resilience, often at lower doses than free drugs. Translation now hinges on standardized potency assays, biodistribution profiling in metabolically diseased hosts, long-term safety, and industrial control of critical quality attributes. This review integrates pathophysiologic rationale, design rules, targeting strategies, efficacy readouts, and manufacturing considerations to chart a practical route for first-in-human evaluation of EMNs in obesity-driven T2D.
Keywords: exosome-mimicking nanoparticles, obesity, type 2 diabetes, targeted RNA delivery, metabolic inflammation
CITE AS: Muhindo Edgar (2026). Exosome-Mimicking Nanoparticles: Next-Generation Therapeutics for Obesity-Induced Type 2 Diabetes. IAA Journal of Scientific Research 13(1):135-140.